Praxis Precision reports sustained seizure reduction with relutrigine, announces Phase 3 trial design

Praxis Precision Medicines, Inc.

Updated EMBOLD open-label data (n=12) show sustained seizure reduction and increased seizure-free periods through 11 months of relutrigine treatment in SCN2A/SCN8A DEEs.
Announced EMERALD Phase 3 trial design: randomized, placebo-controlled, 160 patients aged 2–65 years, 16-week treatment period.
Plans to nominate development candidate for PRAX-100, an antisense oligonucleotide targeting SCN2A loss-of-function in autism, in mid-2025.
Corporate presentation furnished as Exhibit 99.1 includes program updates provided at May 2, 2025 investor event.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.